Free Trial

GSK (GSK) Competitors

GSK logo
GBX 1,395.50 +5.50 (+0.40%)
As of 11:54 AM Eastern

GSK vs. AZN, ITH, SOPH, HCM, INDV, GRI, SLS, ERGO, SLN, and AMYT

Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), HUTCHMED (HCM), Indivior (INDV), Grainger (GRI), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Silence Therapeutics (SLN), and Amryt Pharma (AMYT). These companies are all part of the "pharmaceutical products" industry.

GSK vs. Its Competitors

GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

45.3% of GSK shares are held by institutional investors. Comparatively, 51.0% of AstraZeneca shares are held by institutional investors. 1.6% of GSK shares are held by insiders. Comparatively, 0.0% of AstraZeneca shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GSK has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

In the previous week, AstraZeneca had 4 more articles in the media than GSK. MarketBeat recorded 6 mentions for AstraZeneca and 2 mentions for GSK. AstraZeneca's average media sentiment score of 0.19 beat GSK's score of -0.12 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
AstraZeneca
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.3%. AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.3%. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 64.1% of its earnings in the form of a dividend.

AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK8.02% 18.08% 9.56%
AstraZeneca 13.01%17.76%7.68%

GSK currently has a consensus target price of GBX 1,725, suggesting a potential upside of 23.61%. AstraZeneca has a consensus target price of GBX 8,380, suggesting a potential downside of 17.99%. Given GSK's higher probable upside, equities research analysts clearly believe GSK is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK£31.14B1.82£2.50B£61.9122.54
AstraZeneca£66.95B2.94£8.71B£364.8328.01

Summary

AstraZeneca beats GSK on 11 of the 17 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GSK vs. The Competition

MetricGSKDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£56.63B£76.08B£5.45B£2.96B
Dividend Yield4.25%2.50%5.22%5.02%
P/E Ratio22.5423.1727.24147.41
Price / Sales1.82158.68426.37240,143.56
Price / Cash8.1517.5926.2127.97
Price / Book4.232.997.924.55
Net Income£2.50B£3.43B£3.17B£5.90B
7 Day Performance0.40%-0.19%4.40%1.27%
1 Month Performance-7.64%-3.54%2.64%4.62%
1 Year Performance-7.64%-0.96%35.04%82.58%

GSK Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GSK
GSK
2.962 of 5 stars
GBX 1,395.50
+0.4%
GBX 1,725
+23.6%
-7.0%£56.63B£31.14B22.5470,212
AZN
AstraZeneca
1.9287 of 5 stars
£101.20
-1.0%
GBX 6,303.50
-37.7%
-14.3%£194.71B£66.95B27.7483,500
ITH
Ithaca Energy
N/AGBX 157.60
-0.4%
N/A+18.1%£3.29B£3.55B18.00220
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
HCM
HUTCHMED
N/AGBX 227
+3.7%
N/A-21.3%£2.46B£771.01M-57.941,760
INDV
Indivior
3.1009 of 5 stars
GBX 1,084
+9.9%
GBX 1,650
+52.2%
-3.3%£1.69B£1.40B-898.791,000Gap Up
GRI
Grainger
3.6288 of 5 stars
GBX 220.02
-1.7%
GBX 317.50
+44.3%
-13.5%£1.62B£276.05M-1,466.79372Dividend Increase
SLS
Standard Life UK Smaller Companies Trust
N/AN/AN/AN/A£715.41M£222.48M3.3710
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down

Related Companies and Tools


This page (LON:GSK) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners